Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-Azaadenosine is a small molecule adenosine analog that acts as a potent inhibitor of Adenosine Deaminase Acting on RNA 1 (ADAR1). ADAR1 is an enzyme responsible for the conversion of adenosine to inosine (A-to-I) in double-stranded RNA transcripts, a process critical for regulating innate immune responses and RNA stability. In the context of pulmonary hypertension (PH) research, 8-azaadenosine has been used to demonstrate that ADAR1 deficiency promotes endothelial apoptosis and vascular remodeling by dysregulating the circadian gene Nocturnin (NOCT). While primarily used as a research tool to study RNA editing and innate immunity, its inhibition of ADAR1 has been shown to worsen indices of PH in experimental models, highlighting the protective role of ADAR1-mediated RNA editing in the pulmonary vasculature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-azaadenosine.